Tag: Approval

On Jan. 14, AbbVie‘s (NYSE:ABBV) Rinvoq received approval from the U.S. Food and Drug Administration (FDA) to treat adults and children at least 12 years old with moderate-to-severe atopic dermatitis (eczema) whose condition didn’t respond to other medicines.  What led the FDA to approve Rinvoq for its third indication? And how much of a boost […]